Alcon Reports Q2 Results, Highlighting 4 Percent Sales Increase and Acquisition of STAAR Surgical

GENEVA—Alcon (SIX/NYSE:ALC), a global leader in eyecare, reported its financial results for the three- and six-month periods ending June 30, 2025. For the second quarter of 2025, sales were $2.6 billion, up 4 percent on a reported basis and up 3 percent on a constant currency basis, as compared to the same quarter of the previous year. Reported net sales for the first half of 2025 were $5.0 billion, up 2 percent versus the first half of 2024. Excluding unfavorable currency impacts of 1 percent, sales were up 3 percent on a constant currency basis. The company updated its 2025 outlook, with full-year net sales now expected to be in a range of $10.3 billion to $10.4 billion, down from the May projection of $10.4 billion to $10.5 billion.